Introduction

Multicentric Castleman disease (MCD) is a polyclonal B-lymphoproliferative disorder
characterized by inflammatory flares including fever, cachexia, lymphadenopathy, splenomegaly, cytopenias, and hypoalbuminemia [1] [2] [3] . MCD was first recognized as an idiopathic condition 2, 4 . More recently, a form caused by Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), has been recognized [5] [6] [7] [8] . Almost all cases of MCD in the setting of HIV are KSHV-associated 9, 10 . While the symptoms of KSHV-MCD may wax and wane, the disease is almost universally fatal if untreated 8, 11 .
KSHV is also the etiologic agent of Kaposi sarcoma (KS) and primary effusion lymphoma (PEL) [12] [13] [14] . Its life cycle is characterized by latent and lytic phases [15] [16] [17] [18] [19] and its genome is notable for having pirated several genes homologous to cellular genes, including a viral homolog of human interleukin-6
(hIL-6) called viral IL-6 (vIL-6) [20] [21] [22] [23] [24] [25] . Viral IL-6 can activate cells by binding to the broadly-expressed gp130 subunit for the IL-6 receptor without involving the specific IL-6 receptor alpha (CD126) chain, thus potentially activating a broader range of cells 26 ; it may also have intracellular actions in KSHVinfected cells ,27,28 . Compared with hIL-6, vIL-6 is about one thousandth less potent in activating the IL-6 receptor 29 . KSHV can also induce expression of cellular cytokines including IL-6 and IL-10 30, 31 .
KSHV-MCD is unique among herpesvirus-associated lymphoproliferative disorders in that a proportion of the pathogenic plasmablasts express KSHV in a lytically active form 10, 11, 16, 31 . Involved lymph nodes demonstrate hypocellular germinal centers with KSHV-infected polyclonal but monotypic plasmacytoid cells predominantly in the intrafollicular area 6, 11, 32, 33 . A proportion of the KSHV-infected cells express lytic genes, in particular vIL-6 6 . Notably though, B lymphocytes in affected nodes are largely uninfected plasmacytoid cells that can produce hIL-6 but not vIL-6 6, 33, 34 .
Many clinical manifestations of idiopathic MCD are thought to be caused by overexpression of human IL-6 4, 35, 36 . Overexpression of IL-6 in murine models gives rise to a syndrome resembling MCD 37 .
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elevated KSHV viral loads and dysregulation of other cytokines including hIL-6, resolving with symptom resolution [40] [41] [42] . While both vIL-6 and human cytokines including hIL-6 have been studied separately in small KSHV-MCD cohorts, their respective roles and relative importance remain undefined. Some studies have reported high vIL-6 levels in KSHV-MCD and hypothesized that this was the principal cause of the inflammatory symptoms 43 . Others have noted that much vIL-6 remains intracellular, acting through autocrine signaling, and that it is therefore unlikely to be responsible for systemic symptoms 28 . Even if both cytokines contribute, as has been suggested by one murine model, it is possible that their contribution may be distinct or complementary 44 . We therefore explored the role of vIL-6, hIl-6 and other cytokines in the pathogenesis of KSHV-MCD within a prospective natural history study.
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Methods
Study population
Twenty one patients with KSHV-MCD confirmed by histopathology were studied. These patients were enrolled in a clinical research protocol to explore the natural history and treatment of the disease.
Treatments evaluated included high dose zidovudine in combination with valganciclovir 45 ; rituximab in combination with liposomal doxorubicin; and rituximab in combination with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH). Two patients who enrolled on this protocol were also studied before entry on a separate protocol to study laboratory parameters. Both protocols were approved by the National Cancer Institute Institutional Review Board. All patients gave written informed consent in accordance with the Declaration of Helsinki.
Clinical disease and response assessment
In the absence of a consensus definition of a KSHV-MCD acute episode (or clinical flare) 46 we prospectively defined a flare requiring treatment in the protocol as the presence of at least one clinical symptom (e.g. fever, sweats, or cachexia) and one laboratory abnormality (e.g. hyponatremia,
hypoalbuminema, anemia or thrombocytopenia) attributed to KSHV-MCD in addition to the pathological diagnosis; this definition has since been published in a pilot treatment study 45 . Subsequent to the commencement of the present study, an alternate definition of a flare (or attack) was published by the French Agence Nationale de Recherche sur le SIDA (ANRS) 47 ; for the purposes of comparison, we have retrospectively classified the clinical flares analyzed here according to the ANRS scheme and also using treatment guidelines used in two other recent prospective studies of MCD 48, 49 . Symptom severity was graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0 50 .
Patients with clinical flares received one of the investigational regimens, while those with subclinical disease underwent active surveillance. Glucocorticoids were also used in some patients, especially during the initial treatment, and highly active antiretroviral therapy (HAART) initiated in 6.
patients where this had not already occurred.
In the absence of a consensus definition of a clinical remission of KSHV-MCD 46 , evaluation for remission was performed using clinical and biochemical response criteria as previously described 45 . To be considered a remission for the current analysis, patients had to have complete responses in clinical and biochemical parameters, but not necessarily radiographic parameters; we excluded radiographic changes as we observed during a prior treatment study that in some cases minor splenomegaly and/or lymphadenopathy persisted after resolution of other abnormalities and did not clearly indicate persistent active disease 45 . In some cases, mild isolated hematologic and biochemical abnormalities that were attributable to HIV, drugs, or intercurrent illness, but not KSHV-MCD, persisted at remission. Notably these criteria are more stringent than those employed in other interventional KSHV-MCD studies, where normalization of laboratory abnormalities has not generally been required in determining response [47] [48] [49] .
KSHV quantitative real-time PCR for assessment of viral load in peripheral blood mononuclear cells (PBMC)
PBMC were isolated from blood and DNA isolated using the QIAamp DNA blood mini kit (Qiagen, Valencia, CA). DNA quality and concentration was assessed by optical density using Nanodrop1000 (Thermo Scientific, Wilmington, DE). DNA concentration was adjusted to 250 ng per 10 µL for two quantitative real-time PCR assays developed using TaqMan® (Applied Biosystems, Foster City, CA). KSHV DNA was detected using previously reported primers for the K6 gene region. Cellular equivalents were determined using a quantitative assay for human endogenous retrovirus 3 (ERV-3).
Samples were tested in triplicate for both assays, averaged, and reported as viral DNA copies per million
PBMCs.
Viral IL-6
Viral IL-6 was measured using a modified version of a sandwich ELISA previously described 43 , using clone v6m 31.2.4 mouse monoclonal anti-vIL-6 antibody to coat the plates and then rabbit polyclonal anti-vIL-6 antibody, and goat anti-rabbit antibody conjugated to horseradish peroxidase. The limit of detection was 1560 pg/ml, and the assay did not detect hIL-6 added to serum at concentrations up to 10,000 pg/mL 45 . Samples were tested in duplicate and the results averaged. As we were undertaking paired analyses in patients with known KSHV-MCD, we utilized 1560 pg/mL as the lower limit of detection consistent with a previous study using this assay 45 .
Human cytokines
Serum levels of hIL-6, IL-1β, IL-8, IL-10, IL-12 p70, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were evaluated using the MSD Multiarray® Proinflammatory 7-plex Assay, and serum levels of IL-5 were evaluated using the MSD Multiarray® Singleplex IL-5 Assay (both Meso-Scale Discovery, Gaithersburg, MD), all with the Sector® Imager. Cross-reactivity of vIL-6 was tested in the Meso-Scale IL-6 assay (which uses the same antibodies as the Multiarray® Proinflammatory 7-plex assay), by diluting vIL-6 in a protein-containing kit diluent. The Meso-Scale hIL-6 assay did not detect vIL-6 at concentrations up to 20,000 pg/ml.
Other assays
Plasma HIV-1 mRNA was measured by quantitative RNA polymerase chain reaction using Roche Amplicor® HIV-1 Monitoring Kits (Roche Diagnostic Systems, Branchburg, NJ). CD4 counts were assessed by fluorescent-activated cell sorting (Beckman Coulter, Brea, CA). CRP was assayed using the Siemens Dimension Vista platform (Siemens AG, Munich, Germany). From study inception until May 2009, a standard sensitivity assay (sCRP) was used (upper limit of normal 13.0 mg/L). This was subsequently replaced by a high sensitivity assay (hsCRP) using the same platform (upper limit of normal 
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Statistical analysis
Paired analyses of the relative difference between each cytokine and KSHV VL during the first flare and during remission were performed using Wilcoxon signed rank tests. Given the relatively high threshold of the vIL-6 assay and high proportion of values at or below the detection threshold, vIL-6 values were categorized as detectable (>1560pg/ml) or undetectable, with changes from first flare to remission assessed using the McNemar test for paired categorical data.
Univariate associations between continuous clinical parameters (hemoglobin, sodium, albumin, temperature and platelet count), each human cytokine, and KSHV VL (log 10 transformed) and between human cytokines and KSHV VL were determined using a Spearman rank correlation. Associations between dichotomous clinical parameters and human cytokines or KSHV VL were evaluated using a Wilcoxon rank sum test. For the reasons above, for association analyses involving vIL-6, values were categorized into three ordered categories: undetectable; detectable below 5500pg/mL; and detectable above 5500pg/mL (the cutoff between the two higher categories being approximately the median of subjects with detectable vIL-6). Then the association between ordered vIL-6 and continuous clinical parameters, human cytokines, and KSHV VL was evaluated using the Jonckheere-Terpstra test for trend, and that with dichotomous clinical parameters was evaluated using the exact Cochran-Armitage trend test.
Based on results from the univariate associations, linear regression models were developed in order to determine the relationships between flare-associated cytokines and individual continuous clinical parameters. Prediction of GI and respiratory symptoms was performed using logistic regression analysis after first performing a screening analysis for associations using a Wilcoxon rank sum test for the continuous cytokines and an exact Cochran-Armitage test for the categorized vIL6 values.
As this is a hypothesis-generating study, analyses were considered exploratory, with no formal correction for multiple comparisons. Given the number of comparisons, p-values <0.01 were interpreted as being significant, while p values from 0.01 to 0.05 indicated trends. All p-values are two-tailed.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 
9.
Results
Patient characteristics
Flare characteristics
Clinical and laboratory parameters observed during the 34 flares and 20 first remissions are shown in Table 1 . The most common clinical manifestations during flares were fever and sweats; gastrointestinal disturbances including anorexia, early satiety, nausea, and xerostomia; and respiratory symptoms including cough, dyspnea, and nasal obstruction or discharge; fatigue was also common. Neurological, dermatological, and rheumatologic symptoms were observed in a minority of flares, and included cognitive disturbance, neuropathic pain; rash and cutaneous drug hypersensitivity reactions; joint pain, and myalgias respectively. The median grade of the most severe symptom present for each flare,
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including fever, by CTCAE guidelines was 2 (range 1-3) and median number of symptoms present 4 (2- 
KSHV activity and cytokines during flares
We first sought to identify cytokines and viral parameters that were associated with clinical flares. To avoid statistical bias from patients with multiple flares, for this part of the analysis flareassociated parameters were identified using the first flare for each enrolled patient compared with their remission. KSHV VL was near universally elevated at flare onset (20 of 21 initial flares, 95% and 32 of 34 flares overall, 94%; Figure 1 and Table 2 ). Median VL in PBMCs during flares was 22,400 copies/10 6 PBMCs (range 0-3,913,000; p<0.0001 for initial flare compared with remission). In the two flares where KSHV VL was not elevated at onset, it subsequently became elevated during the flare. In a minority of instances (6, 30%), we observed detectable KSHV VLs persisting at the time of complete remission, though at lower levels than those seen in flares; median KSHV VL during remissions was 0 copies/10 6 PBMCs, range 0-2200.
Five cytokines measured were significantly elevated at initial flare when compared with remission ( Figure 1 and Table 2 ): viral IL-6 (median during all flares 2068 pg/ml, range <1560-20,500;
P=0.0039 for initial flare compared with remission); hIL-6 (median 24.0 pg/ml, range 1. 
Cytokine profiles during flares
We then attempted to assess the respective contribution of vIL-6 and hIL-6 in the development of flares. Serum vIL-6 during flares was not associated with serum hIL-6 during the same flares (P=0.27) ( Figure 2d ). Observed flares fell into three distinct IL-6 profiles ( Figure 3 ): some were associated with elevations of vIL-6 only (2 flares, 6%), some were associated with hIL-6 elevations only (17 flares, 50%), and the remainder were associated with elevations in both vIL-6 and hIL-6 (13 flares, 38%; hereafter called h+vIL-6 flares). In 2 cases (6%), neither vIL-6 nor hIL-6 were elevated at flare onset, but in both cases hIL-6 (but not vIL-6) became elevated later during the flare.
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In the 11 patients in whom more than one flare was observed on study, flare profile was conserved in 8 of the 13 subsequent flares (61.5%). This included two patients who each experienced three flares of the same profile while on study (one with hIL-6 only flares and one with h+vIL-6 flares).
Neither of the patients with vIL-6 only flares experienced subsequent flares.
Cytokine profiles and clinical and laboratory disease manifestations
As vIL-6 can potentially bind to and activate a wider array of cell types than hIL-6, we explored the possibility that there were differences in the clinical and laboratory manifestations of the various flare profiles. The characteristics of all observed flares are shown in Table 3 ; due to the small number of vIL-6-only flares statistical comparisons are made between hIL-6 only flares and h+vIL-6 flares. We observed no difference between flare types in symptomatic severity or symptomatic phenotype judged by the presence or absence of particular symptom groups or of KS. As treatments were not standardized across the cohort, our ability to assess for differences in therapeutic response or duration of remission was limited; nonetheless we observed no clear difference in these outcomes between flare types. However, we did observe significant differences in several laboratory, virological and cytokine parameters, each in the direction of increased severity for h+vIL-6 flares compared with those with hIL-6 alone. In particular, CRP elevation and hyponatremia were both more pronounced in h+vIL-6 flares, and there was also more severe thrombocytopenia in h+vIL-6 flares. KSHV VL was likewise higher in h+vIL-6 flares compared with hIL-6 only flares. We also observed significant differences in the levels of two flare-associated cytokines, IL-10 and IL-5. No difference in TNF-α or the levels of non-flare-associated cytokines between differing h/vIL-6 flare profiles was seen (latter data not shown).
Individual cytokines and clinical and laboratory disease manifestations
To further assess the contribution of individual cytokines to the clinical and laboratory manifestations of KSHV-MCD, we explored their relationship using multiple linear regression models.
Given the relatively non-specific nature of the symptoms observed, we grouped symptoms into groups
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within organ systems (e.g. gastrointestinal or respiratory) for this portion of the analysis. We selected two symptom groups (respiratory and gastrointestinal organ systems), each categorized as present or absent together with five quantitative parameters: temperature, hemoglobin, platelet count, sodium and albumin.
Backward selection logistic regression was performed to identify the cytokines most predictive of each individual manifestation, using all observed flares and remissions treated as independent events.
The primary predictors of each clinical and laboratory manifestation are shown in Table 4 , together with the predictive model derived for each. For fever and respiratory and gastrointestinal symptom groups, the cytokine best predictive of the presence of symptoms was hIL-6. For laboratory manifestations , hIL-6 was again a key predictive element while vIL-6 emerged as an independent predictor for hemoglobin, sodium and albumin. Human IL-6 was a predictor in all regression models except that for albumin, where vIL-6 and IL-1β were the key predictors. For each quantitative manifestation (laboratory manifestations and temperature), Table 4 
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Discussion
This prospective analysis of patients studied during symptomatic flares and subsequent remissions provides new insights into the pathogenesis of KSHV-MCD, and has implications for therapy developement. By simultaneously examining KSHV viral loads, the virally encoded cytokine vIL-6, and other pro-inflammatory human cytokines including hIL-6, we were able to shed light on their respective roles in the symptomatology of KSHV-MCD. With regard to the analysis of vIL-6 and hIL-6, the most striking observation was that either hIL-6 or vIL-6 appeared to be sufficient to induce flares: individual flares were associated with increases in vIL-6, hIL-6, or both. Notably too, KSHV viral load assessed in PBMCs was highly correlated with KSHV-MCD disease activity regardless of the cytokine profile and with implicated flare-associated cytokines.
Given preclinical evidence that vIL-6 can activate a wider range of cells than hIL-6, and our observations that some flares were uniquely associated with one or the other of these cytokines, we were interested to see if differing cytokine profiles were associated with variations in disease manifestations.
Overall, hIL-6 was most closely associated with several key manifestations, including fever, anemia and hypoalbuminemia. These are consistent with the known downstream targets of IL-6, including promoters for albumin and hepcidin and its role as a central pyrogen 52, 53 . We could not discern a clear difference in clinical phenotype between the three v/hIL-6 profiles 27,28 . Nonetheless, the data suggested that vIL-6 might be more strongly associated with the development of hypoalbuminemia than hIL-6 and also played a role in the development of anemia and hyponatremia.
Surprisingly, we did not detect a clinical correlate of IL-10 dysregulation when adjusted for v/hIL-6 in this analysis despite the very high levels seen at flares. It is also notable that neither IFN-γ nor IL-12p70, both targets of IL-10, were elevated. It is possible that any clinical effects of hIL-10 may be masked in our analysis by its close correlation with hIL-6. IL-10 may also be influencing other, unmeasured, clinical sequelae of active KSHV-MCD (perhaps including elevated risks of infection) 54 .
Based on its known functions, it could also be that IL-10 is acting as facilitator of viral immune evasion.
It is also known to have complex effects on developing B cells, and that these are acting to promote 
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survival of KSHV-infected B cells. Similarly the trend to depressed IL-5 may influence manifestations that were not assessed here, including perhaps allergic predisposition.
Our ability to evaluate the role of secreted vIL-6 in this study was limited by the relatively high cutoff of the assay, which almost certainly contributed to some patients with circulating vIL-6 being undetectable. It is likely that this contributed both to the number of flares we observed in which hIL-6 was elevated in the absence of vIL-6, and to the relatively poor predictive power of vIL-6 in linear regression models. Even with this limitation, it is noteworthy that the study identified a role for vIL-6.
Unlike hIL-6, vIL-6 is poorly secreted and it has been postulated that its main role is in intracellular signaling 27, 28 . As such, it has been questioned as to whether secreted or systemic vIL-6 plays any role in KSHV-associated disease pathogenesis. The results here, and in particular the flares in which we observed elevated vIL-6 but not hIL-6, suggest that serum vIL-6 indeed plays an important role in KSHV-MCD pathogenesis and disease manifestations. Further analyses with more sensitive assays for vIL-6 will be needed to shed further light on its role. PBMCs. For IL-6 and TNF-α, the midpoint of levels found in 9-10 normal donors using the same method is shown; other human cytokines illustrated were not detected in panels of 9-10 normal donors 47 .
Note that vertical scales differ.
